news release
View printer-friendly version |
<< Back |
Remain on track to resubmit FUROSCIX® NDA with the FDA by mid-year 2020
Initiating FUROSCIX pre-commercialization and product positioning efforts
Strong balance sheet; ending 2019 with
Guiding 2020 quarterly GAAP expenses of
Business Update
-
Remain on track to resubmit the FUROSCIX New Drug Application (NDA) under the current 505(b)(2) approval pathway with the
U.S. Food and Drug Administration (FDA) by mid-year 2020. FUROSCIX is the Company’s lead program for the treatment of congestion in patients with heart failure. - Completed summative human factors validation study of the FUROSCIX On-Body Infusor. Two human factors studies were designed to assess and optimize user interaction with the FUROSCIX On-Body Infusor. The summative validation study included 60 participants including congestive heart failure patients, healthcare providers, and caregivers, who collectively represent the intended users of FUROSCIX. Results from the study support the use of the FUROSCIX On-Body Infusor within the intended use population and environments.
- Device validation and drug stability testing on track to be completed prior to the resubmission of the FUROSCIX NDA. The initial phase of the drug stability study was successfully completed with analytical testing of the drug product batches finalized for the initial timepoints. The Company also accomplished a key aspect of the device validation program in which the adhesive component of the on-body delivery system was shown to be effective in maintaining adherence to the skin of the abdomen in a simulated wear study. Final testing for both the device and drug stability remains on schedule to be completed prior to the resubmission of the FUROSCIX NDA.
- Commenced initial activities on FUROSCIX pre-commercialization efforts. As development activities for FUROSCIX near completion, the Company has begun to turn attention to pre-commercialization efforts. The Company will be focused on specific pre-commercialization activities including establishing a managed care advisory board, contracting with a specialty pharmacy network, and conducting market research to prepare FUROSCIX product messaging and positioning. These pre-commercialization activities will be staged as appropriate to efficiently follow FUROSCIX’s regulatory progress.
As part of these efforts, the Company participated in Heart Failure Awareness Week,
“2019 was a very productive year for scPharmaceuticals,” said
Fourth Quarter and Year End 2019 Financial Results and Financial Guidance
scPharmaceuticals reported a net loss of
scPharmaceuticals reported a net loss of
scPharmaceuticals ended the fourth quarter with
Based on the Company’s current operating plan, scPharmaceuticals forecasts 2020 expenditures of
About FUROSCIX
FUROSCIX is a proprietary furosemide solution formulated to a neutral pH to allow for subcutaneous infusion via a wearable, pre-programmed on-body drug delivery system, for outpatient self-administration. FUROSCIX is being developed for treatment of congestion, or fluid overload, in patients with heart failure. FUROSCIX has the potential to provide an outpatient alternative for the treatment of worsening heart failure due to congestion.
About scPharmaceuticals
scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions. The Company’s lead programs focus on the subcutaneous, self-administration of IV-strength treatments in heart failure and infectious disease. scPharmaceuticals is headquartered in
Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding the planned resubmission of the FUROSCIX NDA, including potential timing of, and the Company’s expected progress towards, the resubmission and the advancement of the Company’s device verification and validation studies, the Company’s planned efforts to prepare for commercialization of FUROSCIX, and the Company’s 2020 financial guidance, including forecasted cash expenditure. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Company will not resubmit the FUROSCIX NDA in the expected timeframe or at all, the ability of the FUROSCIX On-Body Infusor to appropriately deliver therapy, the receipt of regulatory approval for the FUROSCIX On-Body Infusor or any of our other product candidates or, if approved, the successful commercialization of such products, the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, and the risk that the results of previously conducted studies will not be repeated or observed in ongoing or future studies involving our product candidates and the risk that the current COVID-19 pandemic will impact the Company’s device validation, drug stability testing and other operations. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in its Annual Report on Form 10-K for the year ended
scPharmaceuticals Inc. | |||||||
Consolidated Statements of Operations and Comprehensive Loss | |||||||
(in thousands, except share and per share data) | |||||||
THREE MONTHS ENDED |
YEAR ENDED |
||||||
2018 |
2019 |
2018 |
2019 |
||||
Operating expenses: | |||||||
Research and development |
|
|
|
|
|||
General and administrative |
2,074 |
2,115 |
13,719 |
8,273 |
|||
Total operating expenses |
5,223 |
10,433 |
29,667 |
32,905 |
|||
Loss from operations |
(5,223) |
(10,433) |
(29,667) |
(32,905) |
|||
Other income (expense) |
2 |
(45) |
(56) |
16 |
|||
Interest income |
491 |
310 |
1,712 |
1,660 |
|||
Interest expense |
(370) |
(646) |
(1,432) |
(1,767) |
|||
Net loss and comprehensive loss |
|
|
|
|
|||
Net loss per share, basic and diluted |
|
|
|
|
|||
Weighted—average common shares outstanding, basic and diluted |
18,569,289 |
18,661,626 |
18,556,126 |
18,600,718 |
|||
scPharmaceuticals Inc. | |||||||
Consolidated Balance Sheet Data | |||||||
(in thousands) | AS OF |
||||||
2018 |
2019 |
||||||
Cash, cash equivalents and restricted cash |
|
|
|||||
Working capital |
85,220 |
70,410 |
|||||
Total assets |
93,755 |
77,283 |
|||||
Term loan |
9,637 |
18,915 |
|||||
Accumulated deficit |
(96,459) |
(129,455) |
|||||
Total stockholders’ equity |
78,744 |
51,365 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20200324005134/en/
781-301-6706
ktaudvin@scpharma.com
339-970-2843
chris.brinzey@westwicke.com
Source: scPharmaceuticals Inc.